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Objective: A better understanding of the biobehavioral mechanisms underlying depression 
in cancer is required to translate biomarker findings into clinical interventions. We tested for 
associations between cytokines and the somatic and psychological symptoms of depression in 
cancer patients and their healthy caregivers.
Patients and methods: The GRID Hamilton Rating Scale for Depression (Ham-D) was 
administered to 61 cancer patients of mixed type and stage, 26 primary caregivers and 38 healthy 
controls. Concurrently, blood was drawn for multiplexed plasma assays of 15 cytokines. Multiple 
linear regression, adjusted for biobehavioral variables, identified cytokine associations with the 
psychological (Ham-Dep) and somatic (Ham-Som) subfactors of the Ham-D.
Results: The Ham-Dep scores of cancer patients were similar to their caregivers, but their 
Ham-Som scores were significantly higher (twofold, p=0.016). Ham-Som was positively 
associated with IL-1ra (coefficient: 1.27, p#0.001) in cancer patients, and negatively associ-
ated with IL-2 (coefficient: −0.68, p=0.018) in caregivers. Ham-Dep was negatively associated 
with IL-4 (coefficient: −0.67, p=0.004) in cancer patients and negatively associated with IL-17 
(coefficient: −1.81, p=0.002) in caregivers.
Conclusion: The differential severity of somatic symptoms of depression in cancer patients and 
caregivers and the unique cytokine associations identified with each group suggests the potential 
for targeted interventions based on phenomenology and biology. The clinical implication is that 
depressive symptoms in cancer patients can arise from biological stressors, which is an important 
message to help destigmatize the development of depression in cancer patients.
Keywords: depression, psychological symptoms, somatic symptoms, cytokines, cancer, 
caregiver
Introduction
Despite decades of research, currently available antidepressants which are based on 
monoamine depletion theories achieve remission of depression in fewer than 40% 
of patients,1 in part due to an inadequate understanding of the pathophysiology of 
depression. Depression in the context of medical illnesses, such as cancer, has an 
even more limited evidence base for the effectiveness of existing antidepressants, 
with meta-analysis of the only five placebo-controlled randomized trials indicating 
no significant difference between groups.2
The inflammatory hypothesis of depression has emerged as a predominant explana-
tory theory for its underlying pathophysiology,3 although the precise pathways and 
biobehavioral mechanisms associated with it have not yet been elucidated.4 This 
hypothesis invokes a stress-activated production of pro-inflammatory cytokines, 
leading to alterations in tryptophan and monoamine metabolism, in autoregulatory 
hypothalamic–pituitary–adrenal (HPA) axis pathways, in neuronal excitotoxicity, 
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and/or in brain trophic factors, all potentially contributing to 
the development of major depression.5 Such stress-activated 
inflammatory responses are likely to be triggered by cancer 
and its treatment.
Biological stressors, such as tumor cell burden, infection, 
or treatment-induced tissue destruction, are a clear source of 
inflammatory activation in cancer patients that may contrib-
ute to depression and other so-called sickness behaviors.6 
Psychological stress may also precipitate inflammation, 
activating the HPA axis, increasing peripheral sympathetic 
tone, and stimulating pro-inflammatory cytokine release 
from immune cells.5 The role of psychological stress in the 
inflammation–depression relationship has been recently 
examined in cancer patients,7 but it is not known whether 
physical and psychosocial stressors elaborate distinct inflam-
matory profiles. However, the heterogeneity of both cancer 
and depression complicates research in this field and may 
contribute to the variability in associations found between 
cytokines and depressive symptoms in cancer patients.8
A better understanding of the phenomenology of depres-
sive symptoms in cancer patients is required to translate 
biomarker findings into clinical interventions. This includes 
distinguishing the inflammatory correlates of biological and 
psychological stress, and the somatic and psychological 
symptom domains of depression. This approach aligns with 
the Mental Health Research Domain Criteria (RDoC) project 
of the National Institute of Mental Health to classify mental 
disorders based on behavioral and neurobiological dimen-
sions, rather than solely on descriptive phenomenology.9 This 
move to considering dimensions of depression, rather than 
categorical diagnoses, parallels the trend in symptom cluster 
research in cancer and may be of value in identifying specific 
pathophysiological pathways to depression.6
Comparing cytokine correlates of the somatic and psycho-
logical symptoms of depression in cancer patients, as well as 
in their healthy primary caregivers, may help to clarify their 
specificity. In noncancer patients, pro-inflammatory cytokines 
have been shown to have higher associations with somatic 
symptoms than psychological symptoms of depression.10–12 
Caregivers of cancer patients are an informative comparison 
group, because they are subject to psychological stress related 
to illness in their spouses, but do not directly suffer from the 
biological stresses of cancer. Psychological stressors com-
mon to cancer patients and their caregivers include alterations 
in family role functioning and intimate relationships, fears 
related to changes in bodily appearance and physical suffer-
ing, alterations in anticipated life trajectory, and existential 
concerns. Caregivers must also contend with the multiple 
roles of caregiving, managing the demands of the family 
and household and often maintaining their own employment. 
Cancer caregivers manifest equivalent or higher levels of 
depressive symptoms compared with cancer patients13 and 
have been understudied in terms of inflammatory markers. 
However, most such investigations have been conducted in 
caregivers of dementia patients, whereas cancer caregivers 
tend to be a younger and healthier population.14
We have separately reported on cytokine associations 
with interview-diagnosed major depression in cancer patients.15 
In this report, we describe cytokine associations with somatic 
and psychological symptoms of depression in these cancer 
patients and their healthy primary caregivers. We examined 
a broad suite of cytokines to identify biomarkers potentially 
contributing to depressive symptoms. Cancer patients were 
expected to present with higher somatic symptoms than care-
givers, and general predictions were that different cytokines 
would be associated with depressive symptoms in both groups. 
Identification of distinct cytokine associations in these groups 
will help to elucidate biobehavioral mechanisms that may 
underlie the inflammatory hypothesis of depression and may 
reveal pathways that can be targeted in the treatment of the 
somatic and psychological symptoms of depression.
Patients and methods
subjects
Cancer patients and their healthy primary caregivers were 
recruited from the outpatient oncology and psychosocial 
oncology clinics at the Princess Margaret Cancer Centre, 
Toronto, Canada. Healthy individuals recruited through 
advertisements in the surrounding university and hospital 
networks were included as a comparison group. All study 
subjects provided informed consent for participation, and 
this study received research ethics board approval from the 
University Health Network, Toronto, Canada.
Exclusion criteria intended to minimize variability in 
cytokine levels and symptom presentation included brain 
malignancy or history of neurological illness or trauma, 
substance abuse or dependence within 1 year, immunization 
within 30 days, blood donation within 60 days, pregnancy 
or use of hormonal contraceptives within 3 months, and the 
presence of any psychiatric comorbidity (except depres-
sion) identified by the Mini International Neuropsychiatric 
Interview.16
A total of 61 cancer patients completed the study, where 
31% (19/61) of whom were diagnosed with major depression 
using the Structured Clinical Interview for Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV (SCID).17 
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Cancers were of mixed type and stage, with the majority 
recruited from either the gastrointestinal (38%) or lung 
cancer clinics (19%) and having late-stage disease (64%). 
A total of 26 primary caregivers were recruited, of whom 
three were diagnosed with major depression. In addition, 
38 healthy controls recruited through hospital notices com-
pleted the study.
assessments
As a continuous measure of depression severity, all subjects 
were administered the 17-item GRID Hamilton Rating 
Scale for Depression (Ham-D) by a single trained research 
assistant,18,19 just prior to blood collection. The GRID Ham-D 
is a semi-structured interview version of the Ham-D,19 in 
which reliability has been improved by a symptom frequency 
by intensity scoring grid. A Ham-D cutoff score of 7 is used 
to screen for depression in psychiatric populations.20 The 
Ham-D has been found to have a four-factor structure com-
prising anxiety, depression, insomnia, and somatic domains.21 
Only the depression (Ham-Dep: depressed mood, suicidal 
thoughts, guilt, work and interests, psychomotor retardation) 
and somatic (Ham-Som: gastrointestinal, general somatic, 
weight loss, sexual symptoms) subfactors were used in this 
study to represent psychological and somatic symptoms of 
depression, respectively.
Health behaviors, medical history (including illnesses 
recorded in the Charlson Comorbidity Index [CCI]22), 
demographic, and biobehavioral variables were collected 
on a study questionnaire, including frequency of smoking, 
alcohol use, caffeine consumption, and exercise habits. 
Medical variables for cancer patients were extracted from 
the electronic medical record, including body mass index 
(BMI), cancer type, stage, and treatment.
Plasma cytokine measurement
The following biobehavioral conditions (at the time of blood 
draw) were stipulated to decrease cytokine variability:23 
1) Females were required to be in the follicular phase of the 
menstrual cycle (confirmed by estradiol and progesterone 
levels on the day of testing); 2) no strenuous physical exer-
cise and no alcohol consumption within the past 48 hours; 
3) no acute or infectious illness, allergic reactions, physical 
injuries, or dental work within the past 2 weeks; 4) all blood 
samples were drawn between 8 am and 10 am, following a 
12-hour overnight fast; and 5) blood samples were collected 
in EDTA Vacutainer® tubes (BD, Franklin Lakes, NJ, USA), 
with plasma separated within 2 hours of collection and frozen 
in aliquots at −70°C until assay.
Multiplexed electrochemiluminescence cytokine immu-
noassays were performed using the Meso Scale Discovery 
(MSD) system and read on a Sector® Imager 2400 (Meso 
Scale Diagnostics, Rockville, MD, USA). All assays were 
conducted in duplicate wells with mean values analyzed, 
from a single manufacturer lot number, using singly thawed 
aliquots. A combination of the MSD standard T helper 
(Th)1/Th2 10-plex panel comprising IFN-γ, IL-1β, IL-2, 
IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, and TNF-α and 
customized cytokine kits comprising IL-6, IL-1ra, IL-12p40, 
IL-17, and IL-2Rα were used. Samples measuring below 
the lower limit of quantification (LLOQ) for the assay were 
treated as 0. The Th1/Th2 panel was selected to ensure a 
broad coverage of pro- and anti-inflammatory cytokines, and 
the additional cytokines for the customized kits were selected 
to investigate important recent pathways of interest (IL-17)24 
or cytokines previously reported in the literature in associa-
tion with depression (IL-6, IL-1ra, and IL-2Rα).25,26
statistical analysis
The total sample size of 125 subjects (including cancer 
patients, caregivers, and healthy controls) was used a priori 
to establish a data analysis plan. The number of allowable 
statistical comparisons was predetermined based on the total 
sample size, with false discovery rate (FDR) correction used 
where specified.
All data were loaded into the R statistical environment 
(v.3.1.1). The descriptive characteristics of the sample were 
compared between cancer patients, caregivers, and healthy 
controls. Categorical variables were compared using the 
Pearson’s chi-square test, while continuous variables were 
compared with one-way analysis of variance (ANOVA).
cytokine level analysis and visualization
The cytokine concentration data were transformed into 
log
2
-space, and infinite values were removed by imposing 
a ceiling of 14 as the maximum of all finite cytokine levels. 
Five of 15 cytokines were selected for analysis in pro- to 
anti-inflammatory cytokine ratios: IL-6:IL-4, TNF-α:IL-4, 
IFN-γ:IL-4, IL-6:IL-10, and IFN-γ:IL-10. Levels of the 
15 cytokines and five ratios were visualized in the R statistical 
environment using the lattice (v0.20-29) and latticeExtra 
(v0.6-26) R package. To determine whether there were sig-
nificant differences between these levels in cancer patients 
vs healthy subjects, and caregivers vs healthy subjects, the 
two-sample non-paired t-test with Welch’s correction for 
heteroscedasticity at the 0.95 confidence level was used, 
with FDR correction applied to the resulting p-values. 
Neuropsychiatric Disease and Treatment 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2906
li et al
The magnitude of the differences was evaluated by finding the 
fold difference of the cancer patients’ and caregivers’ mean 
cytokine levels relative to the healthy controls. Since age and 
sex may contribute to the differing cytokine levels in these 
groups,23 multiple logistic regression analysis was performed 
to adjust for these variables in group-wise comparisons, with 
FDR correction applied to the resulting p-values.
cytokine levels and symptom domains of depression
Ham-Dep and Ham-Som were used to study the relationships 
between cytokine levels and depressive symptom domains 
in cancer patients and caregivers. Multiple linear regres-
sion was performed to determine the coefficients, standard 
errors, and p-values that related each cytokine level or ratio 
to the Ham-D subfactor. This analysis was performed with 
the Ham-D subfactors as continuous variables. The cancer 
patient results were adjusted for the effects of age, sex, 
BMI, active treatment (dichotomized as “on” vs “off”), and 
cancer stage and type (treated as unordered factors). The 
caregiver results were adjusted for the effects of age and 
sex. The adjusted coefficients were visualized using dotmaps 
for cancer patients vs caregivers using lattice (v0.20-29) 
and latticeExtra (v0.6-26) packages in the R statistical 
environment (v.3.1.1).
Results
Demographic and biobehavioral variables across the samples 
are summarized in Table 1. Aside from medical comorbidity 
and exercise habits, there were no significant differences 
between the three groups.
Depression subfactors in cancer patients 
and caregivers
GRID Ham-D depression severity scores for cancer patients, 
caregivers, and healthy controls are summarized in Table 2. 
Mean total GRID Ham-D scores in both the cancer patient 
group (10.1±7.4) and the caregiver group (7.3±7.4) were 
above the typical screening cutoff score of 7,21 and both 
were higher than that in the healthy control group (1.7±2.0). 
Mean total GRID Ham-D scores between cancer patients 
and caregivers were not significantly different from each 
other (p=0.11).
Mean psychological symptom scores (Ham-Dep scores) 
were not significantly different between cancer patients 
and caregivers (3.2 vs 2.7, p=0.57), but the mean somatic 
symptom score (Ham-Som score) was higher in the cancer 
group (2.3 vs 1.2, p=0.016). Among cancer patients, there 
were higher levels in both Ham-Som and Ham-Dep subfactor 
scores (3.5±2.2 and 6.5±3.4, respectively) in those with major 
depression. Among subjects with major depression, cancer 
patients scored highest on the Ham-Som subfactor score 
(3.5±2.2), while caregivers scored highest on the Ham-Dep 
subfactor score (10.0±2.0).
cytokine associations with somatic and 
psychological symptoms of depression
Cytokine associations with GRID Ham-D subfactors in cancer 
patients and caregivers are shown in Figure 1. In cancer 
patients, positive associations with somatic symptoms (Ham-
Som) were found for IL-2Rα (coefficient: 0.89, p=0.009) 
and IL-1ra (coefficient: 1.27, p#0.001). Caregivers showed 
a negative association between Ham-Som and IL-2 (coef-
ficient: −0.68, p=0.02) and positive associations with ratios 
TNF-α:IL-4 (coefficient: 0.40, p#0.001) and IL-6:IL-4 
(coefficient: 0.27, p,0.001).
Psychological symptoms of depression in cancer patients 
(Ham-Dep) were negatively associated with the anti- 
inflammatory cytokine IL-4 (coefficient: −0.67, p=0.004) 
and with the pro-inflammatory cytokine IL-12p70 (coeffi-
cient: −0.41, p=0.025). Two cytokine ratios including IL-4 
were positively associated with Ham-Dep in cancer patients: 
IL-6:IL-4 (coefficient: 0.28, p=0.036) and TNF-α:IL-4 (coef-
ficient: 0.46, p=0.007). Among caregivers, the only significant 
Table 1 characteristics of the sample population
Characteristics Cancer 
patients 
(n=61)
Caregivers 
(n=26)
Healthy 
controls 
(n=38)
p-value
Demographics
sex, female (%) 35 (57) 17 (65) 21 (55) 0.70
Mean income, 
caD (sD)
$88.5K ($42K) $99.8K ($48K) N/a 0.29
Mean age, years 
(sD)
55.5 (11.6) 56.3 (12.0) 43.5 (11.7) 0.36
Ethnicity, n (%)
caucasian 49 (80) 21 (81) 24 (63) 0.081
asian 5 (8) 5 (19) 9 (24)
Other 7 (12) 0 5 (13)
Biobehavioral variables
Mean BMi (sD) 25.2 (5.8) N/a N/a
cci (sD)* 5.0 (2.2) 2.3 (0.6) 2.0 (0.2) ,0.001
smokers (%) 8 (13.1) 3 (11.5) 6 (15.8) 0.94
alcohol (sD) 
(drinks/week)
2.71 (5.47) 3.56 (5.13) 2.01 (2.66) 0.62
caffeine (sD) 
(drinks/week)
21.5 (22.5) 20.7 (14.1) 15.9 (12.5) 0.59
exercise habits 
(sD)**
1.77 (0.75) 1.96 (0.81) 2.41 (0.84) 0.009
Notes: *cci calculated without age. **Mean (sD) exercise habits rated as: 1, 
sedentary; 2, mild regular; 3, occasional vigorous; 4, regular vigorous.
Abbreviations: BMi, body mass index; cci, charlson comorbidity index; N/a, 
not available.
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cytokine relationship found with Ham-Dep was a negative 
association with IL-17 (coefficient: −1.81, p=0.002).
impact of statistical adjustments
Table 3 describes the impact of adjustments in the psycho-
logical symptom (Ham-Dep) analyses in cancer patients and 
caregivers, where the strongest and most statistically signifi-
cant cytokine associations were identified. The association 
of IL-17 with Ham-Dep in caregivers was controlled for sex 
and age, with sex not demonstrating a significant effect (coef-
ficient: −0.16, p=0.89), while age had a small but significant 
effect (coefficient: −0.13, p,0.006).
Table 2 ham-D scores across the sample population
Sample population Mean Ham-D total (SD) Mean Ham-Dep (SD) Mean Ham-Som (SD)
Cancer patients (n=61) 10.1 (7.4) 3.2 (3.5) 2.3 (2.1)
Patients with MD (n=19) 22.7 (7.1) 6.5 (3.4) 3.5 (2.2)
Patients without MD (n=42) 7.2 (5.4) 1.7 (2.3) 1.7 (1.8)
Caregivers (n=26) 7.3 (7.4) 2.7 (3.4) 1.2 (1.4)
caregivers with MD (n=3) 16.6 (5.5) 10 (2.0) 2.7 (1.5)
caregivers without MD (n=23) 5.3 (4.9) 1.8 (2.2) 1.0 (1.3)
Cancer vs caregiver (p-value) 0.11 0.57 0.016
healthy controls (n=38) 1.7 (2.0) 0.53 (0.98) 0.05 (0.23)
Notes: MD determined by sciD interview. ham-Dep, depression subfactor of ham-D; ham-som, somatic subfactor of ham-D.
Abbreviations: ham-D, hamilton rating scale for Depression; MD, major depression; sciD, structured clinical interview for DsM-iV.
Figure 1 cytokine associations in cancer patients and caregivers with depression subfactors.
Notes: (A) Dotmap of cytokine associations with ham-som scores. (B) Dotmap of cytokine associations with Ham-Dep scores. Coefficient strength is represented by the 
size of the circle (blue, negative: orange, positive), with the p-value represented in gray scale.
Abbreviations: ham-D, hamilton rating scale for Depression; ham-Dep, depression subfactor of ham-D; ham-som, somatic subfactor of ham-D.
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For the IL-4 and Ham-Dep association in cancer patients, 
cancer stage and type had large and significant impacts 
(coefficient: −3.75, p=0.001 and coefficient: −4.48, p=0.003, 
respectively), but age, sex, BMI, or treatment did not.
cytokine levels in cancer patients, 
caregivers, and healthy controls
The cytokine associations with depressive symptom scores 
did not always coincide with increased or decreased cytokine 
levels relative to healthy controls. As summarized in Table 4, 
the positive association with somatic symptoms coincided 
with higher plasma levels in cancer patients for IL-2Rα (odds 
ratio [OR]: 4.01, p=0.003), but not for IL-1ra (OR: 1.30, 
p=0.42). Pro-inflammatory cytokines IL-2 (negatively asso-
ciated with somatic symptoms in caregivers) and IL-12p70 
(negatively associated with psychological symptoms in 
cancer patients) were increased in both caregivers (OR: 2.12, 
p=0.009) and cancer patients (OR: 1.58, p=0.003), relative 
to healthy controls.
The strongest and most statistically significant associa-
tions identified were the negative associations with psycho-
logical symptoms for anti-inflammatory cytokine IL-4 in 
cancer patients and pro-inflammatory cytokine IL-17 in 
caregivers. IL-4 was significantly increased in cancer patients 
(OR: 1.93, p#0.001), and IL-17 significantly decreased in 
caregivers (OR: 0.23, p=0.010), relative to healthy controls 
(Table 4).
Positive associations of the IL-6:IL-4 and TNF-α:IL-4 
ratios with somatic symptoms in caregivers and with psy-
chological symptoms in cancer patients coincided with lower 
plasma levels of these ratios in both groups, compared with 
healthy controls; although in contrast to the single-cytokine 
between-group differences described earlier, the ORs were of 
lesser magnitude and of marginal statistical significance (ORs 
from 0.71 to 0.86, p-values from 0.02 to 0.06; Table 4).
Discussion
In this study of cytokines and depressive symptoms in cancer 
patients and their caregivers, we found that cancer patients 
reported more somatic symptoms of depression. The higher 
somatic symptom scores in cancer patients with major 
depression could be explained by overlap with the symptoms 
of cancer and its treatment, but is also consistent with the 
known somatic symptom amplification of depression that 
has been shown to occur with depression.27 Both somatic 
and psychological symptoms were increased in cancer 
patients with major depression, compared to those without 
this psychological disturbance, providing support to retain 
both symptom types in the diagnosis of depression in cancer 
patients.28 However, the observed trend toward a differential 
severity of these symptom domains in cancer patients and 
Table 3 Impact of statistical adjustments on significant associa-
tions with ham-Dep
Variable Coefficient Standard 
error
p-value
IL-17 in caregivers
age −0.13 0.04 0.006
sex (female) −0.16 1.06 0.89
il-17 −1.81 0.50 0.002
IL-4 in cancer patients
age −0.08 0.04 0.034
sex (female) −0.16 0.83 0.86
BMi 0.14 0.08 0.089
active treatment 0.82 0.89 0.36
stage iii/iV −3.75 1.11 0.001
hematologic −4.48 1.40 0.003
il-4 −0.67 0.22 0.004
Note: ham-Dep, depression subfactor of ham-D.
Abbreviations: BMi, body mass index; ham-D, hamilton rating scale for 
Depression.
Table 4 cytokine levels and ratios in cancer patients and caregivers compared with healthy controls
Cytokine Cancer patients vs healthy controls Caregivers vs healthy controls
Fold difference 
(p-value)
OR 
(p-value)
Fold difference 
(p-value)
OR 
(p-value)
il-2 8.51 (,0.001) 3.00 (,0.001) 4.14 (,0.001) 2.12 (0.009)
il-17 1.60 (0.002) 1.57 (0.091) −1.65 (0.009) 0.23 (0.010)
il-4 9.25 (,0.001) 1.93 (,0.001) 8.22 (,0.001) 2.07 (0.009)
il-12p70 3.61 (,0.001) 1.58 (0.003) 3.18 (0.017) 1.45 (0.028)
il-2rα 1.80 (,0.001) 4.01 (0.003) −1.04 (0.77) 0.28 (0.058)
il-1ra 1.30 (0.026) 1.30 (0.42) 1.09 (0.61) 0.71 (0.48)
TNF-α:il-4 −4.06 (,0.001) 0.78 (0.015) −3.97 (0.006) 0.71 (0.042)
il-6:il-4 −3.25 (0.018) 0.86 (0.064) −6.15 (0.007) 0.77 (0.038)
Notes: Fold differences between groups are given, with FDr-corrected p-values. Multiple regression Ors, adjusted for age and sex, are given, with FDr-corrected p-values.
Abbreviations: FDr, false discovery rate; Or, odds ratio.
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caregivers suggests that different mechanistic pathways may 
underlie these symptoms in cancer patients and caregivers. 
A larger sample of depressed caregivers will be required to 
substantiate this possibility.
We identified a negative association between IL-4 and 
psychological symptoms of depression in cancer patients. 
Interestingly, a negative association with IL-4 was also 
the only significant cytokine association found for SCID-
based categorically defined major depression in this patient 
sample,15 suggesting that it may be the biological markers of 
the psychological symptoms that distinguish cancer patients 
with and without major depression. Evaluation of the impact 
of statistical control for biobehavioral variables on this asso-
ciation indicated that cancer stage and type overwhelm any 
effects of age, sex, BMI, or active treatment, which is an 
important consideration for future study designs.
In caregivers, psychological symptoms of depression 
were negatively associated with IL-17, and in this noncancer 
population, age was found to have a significant impact on the 
association. We speculate that the difference in cytokine asso-
ciations with psychological symptoms of depression between 
cancer patients and caregivers may be related to cytokine 
network alterations related to cancer and cancer treatment, 
obscuring alterations evoked purely by psychological stress, 
as represented in the caregiver population.
IL-17 is the primary cytokine produced by Th17 cells, a 
highly pro-inflammatory effector T cell type that functions in 
autoimmunity.29 Th17 actions are countered by inflammation-
suppressing regulatory T cells (Treg), with IL-6 promoting 
differentiation toward Th17.30 Thus, high levels of IL-6 
may be a necessary but insufficient condition in the path-
way to depression, playing more of a mediating role in the 
pathophysiology.
IL-6 has previously been reported in association with 
depression in cancer, particularly the somatic symptom 
domain.31–33 Studies in noncancer populations have also 
reported positive associations of IL-6, as well as TNF-α and 
sIL-2R (soluble IL-2Rα) with somatic symptoms of major 
depression.10,11 Somatic symptoms have also been found to be 
predictive of increased TNF-α levels in women with major 
depression, but not men.12 Somatic symptoms in this study 
were positively associated with IL-2Rα and IL-1ra in cancer 
patients, and negatively associated with IL-2 in caregivers. 
The differences between our results and those of other studies 
may be due to differences in the clinical population, the careful 
attention to biobehavioral confounds which sometimes lack-
ing in other studies, or differences in the construct validity 
of the somatic symptom measures used.
Cytokines are known to have pleiotropic functions and 
operate in interactive networks, reciprocally influencing the 
expression of each other.34 Their pro-inflammatory functions 
inherently trigger a compensatory anti-inflammatory reflex 
system (CIRS),35 with the balance between the two determin-
ing net inflammatory effects. Such network complexities 
may be the basis for our finding of a positive association 
between IL2-Rα, but a negative association with its IL-2 
ligand and somatic symptoms in caregivers. Our exploratory 
analyses of inflammatory:anti-inflammatory cytokine ratios 
also revealed positive associations of both IL-6:IL-4 and 
TNF-α:IL-4 with psychological symptoms in cancer patients, 
but with somatic symptoms in caregivers. These findings 
support our hypothesis that the biobehavioral mechanisms 
and cytokine profiles associated with depression would be 
distinct between the two groups. What might account for 
the apparent divergence in symptom domains associated 
with these cytokines and ratios between cancer patients and 
caregivers is unclear, highlighting it as an area of interest for 
future study in a larger, networked analysis.
Anti-inflammatory approaches for the treatment of 
depression are now being explored.36 Studies suggest that 
nonsteroidal anti-inflammatory drugs (NSAIDs) given solely 
or as adjuncts to antidepressants are more effective than 
placebo in treating the symptoms of depression.37 Whereas 
NSAIDs are broad-acting agents, inhibitors targeting specific 
cytokine pathways such as TNF-α and IL-6 have been shown 
to improve the symptoms of depression in patients with 
rheumatic and other inflammatory conditions.38 Some studies 
have also suggested that antidepressants potentially have 
anti-inflammatory properties,37 and antidepressant response 
has been associated with reductions in pro-inflammatory 
cytokines such as IL-1β, TNF-α, and IL-6.39
However, antidepressant effects of anti-inflammatory 
agents must be explored with an understanding of the under-
lying biobehavioral mechanisms in individual patients. 
Raison et al40 reported an antidepressant effect of infliximab, 
a TNF-α antagonist, but only in the subgroup of patients with 
higher baseline inflammation as measured by high levels of 
peripheral C-reactive protein. Potential specific biobehavioral 
mechanisms identified in this study include a negative asso-
ciation between psychological symptoms of depression with 
IL-4 in cancer patients and IL-17 in caregivers, whereas 
somatic symptoms of depression were positively associated 
with IL-2Rα and IL-1ra in cancer patients and negatively 
associated with IL-2 in caregivers.
Limitations of the current study include the correlational 
nature of the reported associations, which do not permit 
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causal interpretations, and the low number of caregivers 
with major depression recruited. Recruitment of sufficient 
numbers of cancer patients with major depression is often 
a significant barrier in biomarker studies, and recruitment 
of depressed caregivers may be an even greater challenge. 
In addition, BMI data were extracted from the electronic 
medical record and were therefore not available to include in 
statistical adjustments for caregivers or healthy controls.
Conclusion
This study found distinct cytokine associations with Ham-
D-defined somatic and psychological symptom domains of 
depression in cancer patients and caregivers, suggesting that 
there may be distinct therapeutic targets for these symptom 
domains in these populations. This also suggests that there 
are different pathways to depressive symptoms in cancer 
patients and caregivers, which may be differentially precipi-
tated by biological and psychological stressors. The clinical 
implication of such findings is that depressive symptoms in 
cancer patients can be precipitated by biological stressors, 
an important message to help de-stigmatize the emergence 
of depression in cancer patients.
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